Novartis (NYSE:NVS) subsidiary Alcon said today that it acquired intraocular lens developer PowerVision for $285 million. PowerVision is developing fluid-based intraocular lens implants that use the eye’s natural accommodating response to transport fluid in the implanted lens, Fort Worth, Texas-based Alcon said. The fluid-based lens creates a continuously variable monofocal lens using the natural contractions of the eye’s […]
June 16, 2014 by Arezu Sarvestani
Ophthalmic devices maker PowerVision finally put a ribbon on its $30 million Series D funding round, planning on using the funds to advance clinical trials in support of regulatory approvals in Europe and the U.S.
PowerVision is trying to fundraise $30 million, having so far brought in $4 million, according to a regulatory filing.
California-based PowerVision touted another round of fundraising backed by some of the biggest names in medtech.
Breast reconstruction technology company AirXpanders Inc. closed a $10 million Series D funding round to support its tissue expansion devices for breast reconstruction.
The Palo Alto, Calif.-based company plans to use the proceeds to advance investigational device exemptions studies, obtain CE Mark approval in Europe and execute market launches in the U.S., Europe and Australia following clearance of its AeroForm system.
Medtronic Inc. (NYSE:MDT) has signed on as an investor in a $24 million financing round for PowerVision Inc.
The Belmont, Calif.-based PowerVision develops intraocular lenses with a novel technology that uses fluid inside the lens that allows natural forces in the eye to change the lens’ shape and provide better focusing ability.